Katzung Chapter 28: Pharmacological Management of Parkinsonism and Other Movement Disorders and Chapter 29: Antipsychotic Agents and Lithium

Chlorpromazine

1st gen typical antipsychotic,

DA antagonist

Haloperidol

1st gen typical antipsychotic,

DA antagonist

Part of Butyrophenones

Thioridazine

1st gen typical antipsychotic,

DA antagonist,

may C→ QT prolongation

Clozapine

2nd gen atypical antipsychotic,

DA and serotonin antagonist,

C→ agranulocytosis and requires WBC counts

Brexpiprazole Aripiprazole

2nd gen atypical antipsychotic,

DA and serotonin antagonist

-piprazole

Olanzepine Quetiapine Asenapine Cariprazine

2nd gen atypical antipsychotic,

DA and serotonin antagonist

-ine

Lurasidone Risperidone Palidridone Iloperidone

2nd gen atypical antipsychotic,

DA and serotonin antagonist

-idone

Ziprasidone

2nd gen atypical antipsychotic,

dopamine and serotonin antagonist,

C→ QT prolongation

Anhedonia

Inability to experience pleasure from activities usually found enjoyable

Pramipexole

Antiparkinson,

dopamine D3 receptor agonist

Ropinirole

Antiparkinson,

dopamine D2 receptor agonist

Selegiline Rasagiline Safinamide

Antiparkinson,

MAO inhibitor (blocks the metabolism of dopamine)

Entacapone

Antiparkinson,

Catechol-O-methyltransferase inhibitors (blocks the metabolism of dopamine)

Amantadine

Antiparkinson,

antiviral, mechanism unknown may potentiate the synthesis, release or reuptake of dopamine

Apomorphine

Potent non-ergoline,

D2 receptor agonist, used for temporary relief of akinesia during on/off phenomenon

Reserpine

C→ Parkinson's disease-

depletes stores biogenic amines from storage sites including dopamine

Haloperidol phenothiazines

C→Parkinson's disease-

dopamine antagonists

MPTP

C—> Parkinson's disease-

toxic to dopaminergic cells in substantia nigra

Benzotropine Orphenadrine Trihexyphenidyl

Antiparkison- anticholinergic